STAGE III CUTANEOUS MELANOMA AJCC V7

This study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …

This study tests two different three-drug combinations in people with advanced melanoma that has spread or can't be removed by surgery. The drugs include immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinations w…

This study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will take part. The goal is to see if the three-d…

This study tests whether taking a break from two targeted cancer drugs (dabrafenib and trametinib) works as well as taking them continuously for people with advanced melanoma that has a specific BRAF mutation. About 280 participants with stage III or IV melanoma that cannot be su…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in 20 people with advanced melanoma that could not be surgically removed. The mai…

This study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with sta…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find a dose that limits side effects while pot…

This early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …